Wasatch Advisors LP cut its holdings in shares of Certara, Inc. (NASDAQ:CERT – Free Report) by 69.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,272,166 shares of the company’s stock after selling 11,950,915 shares during the period. Wasatch Advisors LP owned about 3.44% of Certara worth $30,051,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds also recently added to or reduced their stakes in CERT. Louisiana State Employees Retirement System purchased a new position in shares of Certara during the 1st quarter valued at about $302,000. SG Americas Securities LLC boosted its stake in shares of Certara by 1,717.4% in the first quarter. SG Americas Securities LLC now owns 906,615 shares of the company’s stock worth $5,168,000 after buying an additional 856,729 shares during the last quarter. Corient Private Wealth LLC purchased a new stake in shares of Certara in the fourth quarter worth about $100,000. T. Rowe Price Investment Management Inc. grew its holdings in Certara by 580,097.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 829,683 shares of the company’s stock worth $7,310,000 after acquiring an additional 829,540 shares during the period. Finally, nVerses Capital LLC acquired a new stake in Certara during the fourth quarter worth about $184,000. 73.96% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
CERT has been the subject of a number of analyst reports. Morgan Stanley decreased their price target on Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Stephens dropped their price objective on shares of Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. BMO Capital Markets cut their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Tuesday, May 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Certara in a research note on Friday, May 29th. Finally, Barclays lowered their price target on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Certara presently has a consensus rating of “Hold” and an average target price of $8.85.
Certara Trading Up 6.1%
Shares of CERT stock opened at $5.83 on Friday. Certara, Inc. has a 1-year low of $4.45 and a 1-year high of $13.88. The company has a market cap of $906.17 million, a price-to-earnings ratio of -58.25 and a beta of 1.49. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. The stock has a 50 day simple moving average of $5.58 and a 200-day simple moving average of $6.93.
Certara (NASDAQ:CERT – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The company had revenue of $106.92 million during the quarter, compared to analyst estimates of $106.13 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. Certara’s revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.14 EPS. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, equities research analysts expect that Certara, Inc. will post 0.24 EPS for the current fiscal year.
Certara Company Profile
Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.
The company’s offerings are divided into software tools and consulting services.
Featured Stories
- Five stocks we like better than Certara
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERT – Free Report).
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.
